The pandemic has caused a shift in how drug firms are viewed: their capacity for big-money innovation will give them immunity in the crisis. Widespread homeworking will have broad consequences, from commercial-property values to urban demographics. And a seemingly innocuous Hong Kong history exam is a window into the territory’s increasingly fraught politics.
For full access to print, digital and audio editions of The Economist, subscribe here www.economist.com/radiooffer
See acast.com/privacy for privacy and opt-out information.
📆 2020-05-25 12:00 / ⌛ 00:22:16
📆 2020-05-22 12:12 / ⌛ 00:23:06
📆 2020-05-21 12:11 / ⌛ 00:18:46
📆 2020-05-20 11:58 / ⌛ 00:22:35
📆 2020-05-19 12:17 / ⌛ 00:21:10